RU2563193C2 - Комбинации ингибитора pi3k и ингибитора мек - Google Patents

Комбинации ингибитора pi3k и ингибитора мек Download PDF

Info

Publication number
RU2563193C2
RU2563193C2 RU2012118974/15A RU2012118974A RU2563193C2 RU 2563193 C2 RU2563193 C2 RU 2563193C2 RU 2012118974/15 A RU2012118974/15 A RU 2012118974/15A RU 2012118974 A RU2012118974 A RU 2012118974A RU 2563193 C2 RU2563193 C2 RU 2563193C2
Authority
RU
Russia
Prior art keywords
gdc
compound
patient
combination
present
Prior art date
Application number
RU2012118974/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012118974A (ru
Inventor
БЕЛВИН Маршия
Т. ЧАНЬ Айрис
ФРИДМАН Лори
П. ХЁФЛИХ Клаус
ПРЕСКОТТ Джон
УОЛЛИН Джеффри
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2563193(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2012118974A publication Critical patent/RU2012118974A/ru
Application granted granted Critical
Publication of RU2563193C2 publication Critical patent/RU2563193C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
RU2012118974/15A 2009-10-12 2010-10-11 Комбинации ингибитора pi3k и ингибитора мек RU2563193C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
US61/250,852 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (en) 2009-10-12 2010-10-11 Combinations of a pi3k inhibitor and a mek inhibitor

Publications (2)

Publication Number Publication Date
RU2012118974A RU2012118974A (ru) 2013-11-20
RU2563193C2 true RU2563193C2 (ru) 2015-09-20

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012118974/15A RU2563193C2 (ru) 2009-10-12 2010-10-11 Комбинации ингибитора pi3k и ингибитора мек

Country Status (24)

Country Link
US (1) US20110086837A1 (cg-RX-API-DMAC7.html)
EP (1) EP2488178B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013507415A (cg-RX-API-DMAC7.html)
KR (1) KR101489045B1 (cg-RX-API-DMAC7.html)
CN (1) CN102740851B (cg-RX-API-DMAC7.html)
AR (1) AR078588A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010314287A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008483A2 (cg-RX-API-DMAC7.html)
CA (1) CA2776944A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000913A1 (cg-RX-API-DMAC7.html)
CO (1) CO6531463A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120173A (cg-RX-API-DMAC7.html)
EC (1) ECSP12011865A (cg-RX-API-DMAC7.html)
ES (1) ES2609767T3 (cg-RX-API-DMAC7.html)
IL (1) IL219105A0 (cg-RX-API-DMAC7.html)
MA (1) MA33974B1 (cg-RX-API-DMAC7.html)
MX (1) MX345155B (cg-RX-API-DMAC7.html)
NZ (1) NZ599939A (cg-RX-API-DMAC7.html)
PE (1) PE20121816A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500709A1 (cg-RX-API-DMAC7.html)
RU (1) RU2563193C2 (cg-RX-API-DMAC7.html)
TW (1) TWI428336B (cg-RX-API-DMAC7.html)
WO (1) WO2011054620A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202618B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (a) 포스포이노시타이드 3-키나제 억제제 및 (b) ras/raf/mek 경로의 조절제의 조합물
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
PT3111938T (pt) 2011-04-01 2019-07-10 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
JP6062442B2 (ja) 2011-10-13 2017-01-18 ジェネンテック, インコーポレイテッド 薬剤誘発性低酸症の治療
KR20140097205A (ko) * 2011-10-28 2014-08-06 제넨테크, 인크. 흑색종을 치료하는 치료 조합물 및 방법
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN104334192A (zh) * 2012-04-06 2015-02-04 赛诺菲 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
WO2013157648A1 (ja) * 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
WO2014022680A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014152358A2 (en) * 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
EP3193902A4 (en) * 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
EP3849554B1 (en) 2018-09-11 2025-01-29 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046031A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
WO2007129161A2 (en) * 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
US20090156576A1 (en) * 2005-10-07 2009-06-18 Exelixis Inc. Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (cg-RX-API-DMAC7.html) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
AU685933B2 (en) * 1994-04-01 1998-01-29 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
AU7349801A (en) * 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR101099281B1 (ko) * 2003-03-03 2011-12-26 어레이 바이오파마 인크. p38 억제제 및 그의 사용 방법
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
PE20081679A1 (es) * 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
BRPI0816769A2 (pt) * 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
TR201815685T4 (tr) * 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046031A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US20090156576A1 (en) * 2005-10-07 2009-06-18 Exelixis Inc. Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases
WO2007129161A2 (en) * 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Харкевич Д.А. Фармакология: Учебник. " 9-е изд., доп. и испр. " М.: ГЭОТАР-Медиа, 2006. " 736 с. Olga K. Mirzoeva et al / Basal Subtype and (MAPK)/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition / Cancer Res / January 2009, Vol.69, N2, pages 565-572 *

Also Published As

Publication number Publication date
US20110086837A1 (en) 2011-04-14
KR20120064132A (ko) 2012-06-18
PH12012500709A1 (en) 2012-10-29
CO6531463A2 (es) 2012-09-28
EP2488178B1 (en) 2016-11-16
KR101489045B1 (ko) 2015-02-02
CR20120173A (es) 2012-07-04
TW201118082A (en) 2011-06-01
BR112012008483A2 (pt) 2019-09-24
JP5745678B2 (ja) 2015-07-08
MX345155B (es) 2017-01-18
MX2012004286A (es) 2012-05-22
JP2013507415A (ja) 2013-03-04
IL219105A0 (en) 2012-06-28
AR078588A1 (es) 2011-11-16
CN102740851A (zh) 2012-10-17
AU2010314287A1 (en) 2012-05-03
MA33974B1 (fr) 2013-02-01
WO2011054620A1 (en) 2011-05-12
ECSP12011865A (es) 2012-06-29
ES2609767T3 (es) 2017-04-24
CN102740851B (zh) 2013-12-18
CA2776944A1 (en) 2011-05-12
AU2010314287A2 (en) 2012-07-12
JP2015038110A (ja) 2015-02-26
EP2488178A1 (en) 2012-08-22
NZ599939A (en) 2014-02-28
ZA201202618B (en) 2014-10-29
PE20121816A1 (es) 2013-01-02
RU2012118974A (ru) 2013-11-20
HK1175125A1 (en) 2013-06-28
CL2012000913A1 (es) 2012-09-14
TWI428336B (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
TWI428336B (zh) Pi3k抑制劑及mek抑制劑之組合
Zhao et al. The clinical development of MEK inhibitors
JP2024526145A (ja) Kras g12c阻害剤を含む組合せ医薬及び癌の治療のためのその使用
EP2205242B1 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20200246338A1 (en) Combination therapy
CN113840606A (zh) 给药kras抑制剂治疗癌症
JP6855243B2 (ja) 癌治療のためのアピリモド(apilimod)組成物
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
JP2020079243A (ja) PI3Kインヒビターとc−Metインヒビターの組み合わせ
CN115776889A (zh) 用于治疗非小细胞肺癌的egfr tki
EP4554581A1 (en) Combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors
JP2025530296A (ja) 転移性癌を治療するためのplk1阻害剤と抗血管新生剤の併用
CA3255718A1 (en) Polytherapy involving GDC-6036 and GDC-0077 for cancer treatment
CN117043159A (zh) Kras突变型癌症的治疗
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
HK1175125B (en) Combinations of a pi3k inhibitor and a mek inhibitor
WO2014031856A1 (en) Combination therapy using pi3 kinase and braf inhibitors
Teicher et al. Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models
HK40121691A (en) Methods for treating cancer resistant to cdk4/6 inhibitors
HK40087830A (en) Belvarafenib for use in cancer treatment
HK1145287B (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171012